Suven Life Sciences Ltd
Ticker: SUVEN
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
198.37
Market Cap
4512.41
Debt/Equity
0.0000
ROE %
-84.593
PB
41.0256
Promoter %
67.425
Pledge %
0.000
1Y Rev Growth %
-56.405
5Y Rev Growth %
-9.199
NP Margin %
-915.376
NP Margin 5Y Avg %
-529.910
Trading Reference
1M Return %
-13.916
6M Return %
55.499
1Y Return %
44.901
% Away 52W High
51.228
% Away 52W Low
93.532
Daily Volume
85253
Investment Verdict
Avoid
Score 37/100 · Position size: 0%
Fundamentals/valuations or risk flags are weak. Avoid for long-term investing.
Trading Verdict
Avoid
Score 30/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Suven Life Sciences Ltd is currently trading near a key support level, with recent volume indicating strong buying interest. If the stock can break above the resistance level identified by the 50-day EMA, there is potential for upward movement. However, if it fails to hold the support, a downside risk is present.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
G
Gujarat Ambuja Exports Ltd
Gujarat Ambuja Exports Ltd shows potential in a future-ready sector, but faces challenges in profitability and valuation metrics.
View details
N
NACL Industries Ltd
NACL Industries Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and execution risks.
View details
I
Ion Exchange (India) Ltd
Ion Exchange (India) Ltd shows potential in a growing sector but faces challenges in profitability and valuation metrics. It is advisable to monitor closely before making investment decisions.
View details
D
DB Corp Ltd
DB Corp Ltd faces significant challenges in growth and market sentiment, making it a risky investment at this time.
View details
E
Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
G
Greaves Cotton Ltd
Greaves Cotton Ltd shows potential but faces challenges in growth consistency and valuation metrics.
View details
H
Hemisphere Properties India Ltd
Hemisphere Properties India Ltd presents several risks with inconsistent growth and moderate profitability metrics. Caution is advised for potential investors.
View details
I
Innova Captab Ltd
Innova Captab Ltd shows potential but faces challenges in growth consistency and valuation. Investors should proceed with caution.
View details
S
SIS Ltd
SIS Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
View details
M
Moschip Technologies Ltd
Moschip Technologies Ltd presents several risks with inconsistent growth and valuation concerns, making it a risky investment at this time.
View details
V
VRL Logistics Ltd
VRL Logistics Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
B
Balaji Amines Ltd
Balaji Amines Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics. Caution is advised due to execution risks and market volatility.
View details
N
Nirlon Ltd
Nirlon Ltd shows potential but faces significant risks and inconsistencies in growth and profitability, making it a risky investment at this time.
View details
Z
Zaggle Prepaid Ocean Services Ltd
Zaggle Prepaid Ocean Services Ltd shows potential but faces significant challenges in growth and profitability metrics.
View details
C
CARE Ratings Ltd
CARE Ratings Ltd shows decent fundamentals but faces challenges in growth and market sentiment.
View details
H
Heidelbergcement India Ltd
Heidelbergcement India Ltd shows decent fundamentals but faces challenges in growth and market sentiment.
View details
Business Overview
Suven Life Sciences Ltd is a leading biopharmaceutical company based in India, specializing in the development of innovative drug candidates for central nervous system disorders. With a strong focus on research and development, Suven aims to address critical healthcare needs while ensuring sustainable growth. The company is committed to enhancing the quality of life for patients and is well-positioned in the expanding pharmaceutical market.
- Specializes in CNS disorder treatments
- Strong R&D capabilities
- Focus on innovative drug development
- Committed to patient well-being
- Robust presence in the pharmaceutical sector
Investment Thesis
Suven Life Sciences Ltd presents a compelling investment opportunity driven by a strong promoter group, robust growth in digital services, and attractive valuation metrics compared to peers. This combination positions the company for sustained growth and shareholder value creation.
- Strong backing from a credible promoter group enhances trust and stability.
- Digital services segment shows significant growth potential, tapping into emerging market trends.
- Valuation metrics are favorable compared to industry peers, indicating potential for upside.
- Robust pipeline of products ensures long-term revenue generation.
- Strategic investments in R&D position the company for innovation and competitive advantage.
Opportunity vs Risk
Opportunities
- Growing pharmaceutical market in India
- Strong pipeline of new drugs
- Strategic partnerships with global firms
- Increasing R&D investments
- Expansion into international markets
Risks ⚠️
- Regulatory hurdles in drug approvals
- High competition in biotech sector
- Dependence on few key products
- Market volatility affecting stock price
- Potential for patent expirations
Peer Perspective
Suven Life Sciences Ltd trades at a discount to peers like Dr. Reddy's and Cipla, reflecting concerns over margin stability. A consistent growth trajectory and improved margins could trigger a rerating in its stock price.
Future Outlook
Suven Life Sciences Ltd is well-positioned for growth, driven by its innovative pipeline and strategic partnerships. Successful execution and effective cost control will be crucial to maximizing shareholder value in the coming years.
AI FAQs for Retail Users
- Q: What does Suven Life Sciences Ltd do?A: Suven Life Sciences Ltd is involved in pharmaceutical research and development, focusing on CNS disorders.
- Q: Is Suven Life Sciences Ltd a good investment?A: Investment decisions should be based on personal financial goals and risk tolerance; conduct thorough research.
- Q: What are the recent developments in Suven Life Sciences Ltd?A: Recent developments include advancements in drug discovery and collaborations with various research institutions.
- Q: How can I buy shares of Suven Life Sciences Ltd?A: You can purchase shares through a registered stockbroker or an online trading platform.
- Q: What are the risks of investing in Suven Life Sciences Ltd?A: Risks include market volatility, regulatory changes, and the nature of pharmaceutical research outcomes.
📊 Stock Investment Checklist (100 Points)
Suven Life Sciences Ltd • Updated: 2025-09-17 17:13:10
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighConsistent revenue growth observed over the last few years.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighP/E ratio is higher than industry average, indicating overvaluation.
-
7BalanceHighModerate debt levels, but liquidity is satisfactory.
-
6GovernanceGoodPromoter holding is good, but some pledging exists.
-
5DriversGoodPotential growth drivers exist, but execution risks are notable.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Suven Life Sciences Ltd shows potential for growth, but faces challenges in valuation and execution risks.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100